Identification of and Structural Insights into Hit Compounds Targeting N-Myristoyltransferase for Cryptosporidium Drug Development

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Structure-Based Design of Potent and Selective Leishmania N- Myristoyltransferase Inhibitors

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Structure-Based Design of Potent and Selective Leishmania N- Myristoyltransferase Inhibitors

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

SIRT2 removes ARF6 K3 myristoylation a Alk12 labeling results on

Overview of the obtained crystallographic NMT complexes Crystal

Identification of and Structural Insights into Hit Compounds Targeting N- Myristoyltransferase for Cryptosporidium Drug Development

Frontiers Cryptosporidium parvum Pyruvate Kinase Inhibitors With in vivo Anti-cryptosporidial Efficacy

Plasmodium falciparum NMT substrates are involved in a variety of